Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose

Next Previous
Trial Profile

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostemsavir (Primary) ; Atazanavir; Raltegravir; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; ViiV Healthcare

    • Most Recent Events

    • 08 Oct 2020 Results assessing Fostemsavir exposure-response relationships from Phase II and Phase III studies presented at the 15th International Congress on Drug Therapy and HIV Infection
    • 11 Mar 2020 Results assessing Fostemsavir Exposure-Response Relationships in Treatment-Experienced Hiv Patients from NCT01384734 and NCT02362503,presented at the 27th Conference on Retroviruses and Opportunistic Infections
    • 07 Mar 2019 Efficacy results through Week 192, presented at the 26th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top